Arcutis Biotherapeutics I... (ARQT)
NASDAQ: ARQT
· Real-Time Price · USD
16.29
0.31 (1.94%)
At close: Aug 15, 2025, 10:18 AM
1.94% (1D)
| Bid | 16.29 |
| Market Cap | 1.95B |
| Revenue (ttm) | 263.46M |
| Net Income (ttm) | -93.27M |
| EPS (ttm) | -0.73 |
| PE Ratio (ttm) | -22.32 |
| Forward PE | 64.07 |
| Analyst | Buy |
| Ask | 16.35 |
| Volume | 506,006 |
| Avg. Volume (20D) | 2,217,122.5 |
| Open | 16.11 |
| Previous Close | 15.98 |
| Day's Range | 16.06 - 16.79 |
| 52-Week Range | 8.03 - 17.75 |
| Beta | 1.84 |
About ARQT
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ARQT
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ARQT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsEarnings Surprise
Arcutis Biotherapeutics has released their quartely earnings
on Aug 6, 2025:
Next Earnings Release
Arcutis Biotherapeutics Inc. is scheduled to release its earnings on
Nov 5, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
5 months ago
+12.31%
Arcutis Biotherapeutics shares are trading higher ...
Unlock content with
Pro Subscription
5 months ago
+8.36%
Arcutis Biotherapeutics shares are trading higher after the company reported better-than-expected Q4 financial results.
1 week ago · fool.com
Arcutis (ARQT) Q2 Revenue Soars 164%Arcutis (ARQT) Q2 Revenue Soars 164%
1 month ago · seekingalpha.com
Arcutis Biotherapeutics: A Closer Look At The Atopic Dermatitis DirectionArcutis Biotherapeutics' ZORYVE (roflumilast) offers superior efficacy and safety over current topical treatments for mild-to-moderate atopic dermatitis. The atopic dermatitis market is large and shif...
